VYNE Therapeutics Inc (VYNE)
2.30
+0.10
(+4.55%)
USD |
NASDAQ |
Jun 14, 16:00
2.22
-0.08
(-3.48%)
After-Hours: 20:00
VYNE Therapeutics Research and Development Expense (Quarterly): 3.708M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 3.708M |
| December 31, 2023 | 3.023M |
| September 30, 2023 | 3.318M |
| June 30, 2023 | 7.233M |
| March 31, 2023 | 2.734M |
| December 31, 2022 | 4.279M |
| September 30, 2022 | 5.546M |
| June 30, 2022 | 4.108M |
| March 31, 2022 | 4.452M |
| December 31, 2021 | 4.324M |
| September 30, 2021 | 5.917M |
| June 30, 2021 | 5.048M |
| March 31, 2021 | 4.255M |
| December 31, 2020 | 7.838M |
| September 30, 2020 | 6.623M |
| Date | Value |
|---|---|
| June 30, 2020 | 13.12M |
| March 31, 2020 | 15.95M |
| December 31, 2019 | 11.76M |
| September 30, 2019 | 12.62M |
| June 30, 2019 | 13.46M |
| March 31, 2019 | 15.92M |
| December 31, 2018 | 15.08M |
| September 30, 2018 | 10.67M |
| June 30, 2018 | 16.23M |
| March 31, 2018 | 11.02M |
| December 31, 2017 | 10.55M |
| September 30, 2017 | 8.008M |
| June 30, 2017 | 5.46M |
| March 31, 2017 | 4.992M |
| December 31, 2016 | 4.077M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.734M
Minimum
Mar 2023
15.95M
Maximum
Mar 2020
6.966M
Average
5.297M
Median
Research and Development Expense (Quarterly) Benchmarks
| Geron Corp | 29.37M |
| NovaBay Pharmaceuticals Inc | 0.019M |
| Palatin Technologies Inc | 7.160M |
| iBio Inc | 0.904M |
| Theriva Biologics Inc | 3.459M |